Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 98, Issue , 2014, Pages 321-326

  Gonzalez Dominguez R ^a   Garcia Barrera T ^a   Gomez Ariza J L ^a  

^a UNIVERSITY OF HUELVA   (Spain)

Author keywords

Alzheimer's disease; Biomarkers; Direct infusion mass spectrometry; Lipidomics

Indexed keywords

ARGININE; BIOLOGICAL MARKER; DIACYLGLYCEROL; GUANIDINE; HISTIDINE; IMIDAZOLE; KYNURENINE; OLEAMIDE; PHOSPHOLIPID; PROSTAGLANDIN; PUTRESCINE; TAURINE; LIPID;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIRECT INFUSION MASS SPECTROMETRY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HYPERAMMONEMIA; IONIZATION; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPIDOMICS; MALE; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR WEIGHT; NERVE DEGENERATION; NEUROTRANSMISSION; OXIDATIVE STRESS; PRIORITY JOURNAL; TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; CHEMISTRY; METABOLISM; METABOLOME; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROCEDURES; SERUM;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FEMALE; HUMANS; LIPIDS; MALE; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; MULTIVARIATE ANALYSIS; SERUM;

EID: 84903640571     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.05.023     Document Type: Article

References (55)

1. Nagy Z., Esiri M.M., Jobst K. Relative role of plaques and tangles in the dementia of Alzheimer disease: correlations using three sets of neuropathological criteria. Dementia 1995, 6:21-31.
2. Migliore L., Fontana I., Colognato R., Coppede F., Siciliano G., Murri L. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol. Aging 2005, 26:587-595.
3. Maruszak A., Zekanowski C. Mitochondrial dysfunction and Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:320-330.
4. Storga D., Vrecko K., Birkmayer J.G.D., Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci. Lett. 1996, 203:29-32.
5. Goldsmith P., Fenton H., Morris-Stiff G., Ahmad N., Fisher J., Prasad K.R. Metabonomics: a useful tool for the future surgeon. J. Surg. Res. 2010, 160:122-132.
6. Watson A.D. Lipidomics: a global approach to lipid analysis in biological systems. J. Lipid Res. 2006, 47:2101-2111.
7. Mielke M.M., Lyketsos C.G. Lipids and the pathogenesis of Alzheimer's disease: is there a link?. Int. Rev. Psychiatry 2006, 18:173-186.
8. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J. Neural Transm. 2000, 107:1027-1063.
9. Pettegrew J.W., Panchalingam K., Hamilton R.L., McClure R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 2001, 26:771-782.
10. Mielke M.M., Lyketsos C.G. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?. Neuromol. Med. 2010, 12:331-340.
11. Bazan N.G., Colangelo V., Lukiw W.J. Prostaglandins and other lipid mediators in Alzheimer's disease. Prostag. Oth. Lipid M. 2002, 68-69(68):197-200.
12. Praticò D. The neurobiology of isoprostanes and Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:930-933.
13. Bet L., Calabrese E., Bava L., Magni E., Rapuzzi S., Pezzoli G., Mariani C. Malondialdehyde production features in platelets of Parkinson and Alzheimer patients in physiological aging. Neurosci. Res. Commun. 1999, 25:33-41.
14. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J. Neuroinflamm. 2011, 8:26.
15. Hu C., van der Heijden R., Wang M., van der Greef J., Hankemeier T., Xu G. Analytical strategies in lipidomics and applications in disease biomarker discovery. J. Chromatogr. B 2009, 877:2836-2846.
16. Dunn W.B., Ellis D.I. Metabolomics: current analytical platforms and methodologies. Trends Anal. Chem. 2005, 24:285-294.
17. Weaver P.J., Laures A.M.F., Wolff J.C. Investigation of the advanced functionalities of a hybrid quadrupole orthogonal acceleration time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 2007, 21:2415-2421.
18. Dunn W.B. Current trends and future requirements for the mass spectrometric investigation of microbial, mammalian and plant metabolomes. Phys. Biol. 2008, 5:011001.
19. Want E.J., Nordström A., Morita H., Siuzdak G. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J. Proteome Res. 2007, 6:459-468.
20. Han X., Gross R.W. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J. Lipid Res. 2003, 44:1071-1079.
21. Han X. Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:774-783.
22. Han X., Rozen S., Boyle S.H., Hellegers C., Cheng H., Burke J.R., Welsh-Bohmer K.A., Doraiswamy P.M., Kaddurah-Daouk R. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 2011, 6:e21643.
23. McKahnn G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
24. Bligh E.G., Dyer W.J. A rapid method for total lipid extraction and purification. Can. J. Biochem. Phys. 1959, 37:911-917.
25. Pulfer M., Murphy R.C. Electrospray mass spectrometry of phospholipids. Mass Spectrom. Rev. 2003, 22:332-364.
26. Wang C., Xie S., Yang J., Yang Q., Xu G. Structural identification of human blood phospholipids using liquid chromatography/quadrupole-linear ion trap mass spectrometry. Anal. Chim. Acta 2004, 525:1-10.
27. González-Dominguez R., García-Barrera T., Gómez-Ariza J.L. Iberian ham typification by direct infusion electrospray and photospray ionization mass spectrometry fingerprinting. Rapid Commun. Mass Spectrom. 2012, 26:835-844.
28. Nichols K.K., Ham B.M., Nichols J.J., Ziegler C., Green-Church K.B. Identification of fatty acids and fatty acid amides in human meibomian gland secretions. Invest. Ophthalmol. Vis. Sci. 2007, 48:34-39.
29. Murphy R.C., Barkley R.M., Berry K.Z., Hankin J., Harrison K., Johnson C., Krank J., McAnoy A., Uhlson C., Zarini S. Electrospray ionization and tandem mass spectrometry of eicosanoids. Anal. Biochem. 2005, 346:1-42.
30. 2. Neurochem. Res. 2004, 29:1961-1977.
31. Farooqui A.A., Yang H.C., Horrocks L. Involvement of phospholipase A(2) in neurodegeneration. Neurochem. Int. 1997, 30:517-522.
32. Kosicek M., Kirsch S., Bene R., Trkanjec Z., Titlic M., Bindila L., Peter-Katalinic J., Hecimovic S. Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer's disease patients - a pilot study. Anal. Bioanal. Chem. 2010, 398:2929-2937.
33. Frisardi V., Panza F., Seripa D., Farooqui T., Farooqui A.A. Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. Prog. Lipid Res. 2011, 50:313-330.
34. Carrasco S., Mérida I. Diacylglycerol, when simplicity becomes complex. Trends. Biochem. Sci. 2007, 32:27-36.
35. Shimohama S., Sasaki Y., Fujimoto S., Kamiya S., Taniguchi T., Takenawa T., Kimura J. Phospholipase C isoenzymes in the human brain and their changes in Alzheimer's disease. Neuroscience 1998, 82:999-1007.
36. Zhang D., Dhillon H., Prasad M.R., Markesbery W.R. Regional levels of brain phospholipase Cγ in Alzheimer's disease. Brain Res. Rev. 1998, 811:161-165.
37. Jin J.K., Kim N.H., Lee Y.J., Kim Y.S., Choi E.K., Kozlowski P.B., Park M.H., Kim H.S., Min D.S. Phospholipase D1 is up-regulated in the mitochondrial fraction from the brains of Alzheimer's disease patients. Neurosci. Lett. 2006, 407:263-267.
38. Jin J.K., Ahn B.H., Na Y.J., Kim J.I., Kim Y.S., Choi E.K., Ko Y.G., Chung K.C., Kozlowski P.B., Min D.S. Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease. Neurobiol. Aging 2007, 28:1015-1027.
39. Gonzalez-Dominguez R., Garcia-Barrera T., Gomez-Ariza J.L. Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease. J. Proteomics 2014, 104:66-79.
40. Fonteh A.N., Harrington R.J., Tsai A., Liao P., Harrington M.G. Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids 2007, 32:213-224.
41. Natelson S., Sherwin J.E. Proposed mechanism for urea nitrogen re-utilization: relationship between urea and proposed guanidine cycles. Clin. Chem. 1979, 25:1343-1344.
42. Felipo V., Butterworth R.F. Neurobiology of ammonia. Prog. Neurobiol. 2002, 67:259-279.
43. Hansmannel F., Sillaire A., Kamboh M.I., Lendon C., Pasquier F., Hannequin D., Laumet G., Mounier A., Ayral A.M., DeKosky S.T., Hauw J.J., Berr C., Mann D., Amouyel P., Campion D., Lambert J.C. Is the urea cycle involved in Alzheimer's disease?. J. Alzheimers Dis. 2010, 21:1013-1021.
44. Yatin S.M., Yatin M., Varadarajan S., Ain K.B., Butterfield D.A. Role of spermine in amyloid β-peptide-associated free radical-induced neurotoxicity. J. Neurosci. Res. 2001, 63:395-401.
45. Morrison L.D., Kish S.J. Brain polyamine levels are altered in Alzheimer's disease. Neurosci. Lett. 1995, 197:5-8.
46. Louzada P.R., Lima A.C.P., Mendoça-Silva D.L., Noël F., de Mello F.G., Ferreira S.T. Taurine prevents the neurotoxicity of β-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J. 2004, 18:511-518.
47. Alom J., Mahy J.N., Brandi N., Tolosa E. Cerebrospinal fluid taurine in Alzheimer's disease. Ann. Neurol. 1991, 30:735.
48. Arafat E.S., Trimble J.W., Andersen R.N., Dass C., Desiderio D.M. Identification of fatty acid amides in human plasma. Life Sci. 1989, 45:1679-1687.
49. Fedorova I., Hashimoto A., Fecik R.A., Hedrick M.P., Hanus L.O., Boger D.L., Rice K.C., Basile A.S. Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J. Pharmacol. Exp. Ther. 2001, 299:332-342.
50. Murillo-Rodriguez E., Giordano M., Cabeza R., Henriksen S.J., Diaz M.M., Navarro L., Prospero-Garcia O. Oleamide modulates memory in rats. Neurosci. Lett. 2001, 313:61-64.
51. Heo H.J., Park Y.J., Suh Y.M., Choi S.J., Kim M.J., Cho H.Y., Chan Y.J., Hong B., Kim H.K., Kim E., Kim C.J., Kim B.G., Shin D.H. Effects of oleamide on choline acetyltransferase and cognitive activities. Biosci. Biotech. Biochem. 2003, 67:1284-1291.
52. Chen C., Alder J.T., Bowen D.M., Esiri M.M., McDonald B., Hope T., Jobst K.A., Francis P.T. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J. Neurochem. 1996, 66:1592-1598.
53. Rissman R.A., De Blas A.L., Armstrong D.M. GABA(A) receptors in aging and Alzheimer's disease. J. Neurochem. 2007, 103:1285-1292.
54. Gong C.Y., Li Z., Wang H.M., Liu J., Chen L., Zhang H.W., Wang X., Yang J. Targeting the kynurenine pathway as a potential strategy to prevent and treat Alzheimer's disease. Med. Hypotheses 2011, 77:383-385.
55. Gulaj E., Pawlak K., Bien B., Pawlak D. Kynurenine and its metabolites in Alzheimer's disease patients. Adv. Med. Sci. 2010, 55:204-211.